Translational Research
Volume 155, Issue 5 , Pages 238-246 , May 2010

Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease—KOZANI STUDY

  • Nikolaos P.E. Kadoglou

      Affiliations

    • Department of Cardiology, “Mamatsio” General Hospital, Kozani, Greece
    • Center of Experimental Surgery, Biomedical Research Foundation, Academy of Athens, Greece
    • Corresponding Author InformationReprint requests: Nikolaos P. E. Kadoglou, Department of Cardiology, “Mamatsio” General Hospital, 124 Vosporou str, GR-54454 Thessaloniki, Greece;
    • ,
  • Stilianos Lampropoulos

      Affiliations

    • Department of Cardiology, “Mamatsio” General Hospital, Kozani, Greece
    • ,
  • Alkistis Kapelouzou

      Affiliations

    • Center of Experimental Surgery, Biomedical Research Foundation, Academy of Athens, Greece
    • ,
  • Argirios Gkontopoulos

      Affiliations

    • Department of Cardiology, “Mamatsio” General Hospital, Kozani, Greece
    • ,
  • Efstratios K. Theofilogiannakos

      Affiliations

    • Department of Cardiology, “Mamatsio” General Hospital, Kozani, Greece
    • ,
  • Grigorios Fotiadis

      Affiliations

    • First Department of Internal Medicine, “Hippokratio” General Hospital, Thessaloniki, Greece
    • ,
  • George Kottas

      Affiliations

    • Department of Cardiology, “Mamatsio” General Hospital, Kozani, Greece

Received 28 November 2009 ,Revised 22 January 2010 ,Accepted 23 January 2010.

References 

  1. Wilson PW. Evidence of systemic inflammation and estimation of coronary artery disease risk: a population perspective. Am J Med. 2008;121:S15–S20
  2. Shah A, Mehta N, Reilly MP. Adipose inflammation, insulin resistance, and cardiovascular disease. JPEN J Parenter Enteral Nutr. 2008;32:638–644
  3. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251:471–476
  4. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther. 2005;107:198–211
  5. Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept. 2005;126:233–240
  6. Ronkainen VP, Ronkainen JJ, Hänninen SL, et al. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J. 2007;21:1821–1830
  7. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Visfatin and apelin, new adipokines, and their relation to endothelial function in patients with chronic renal failure. Adv Med Sci. 2008;53:32–36
  8. Farkasfalvi K, Stagg MA, Coppen SR, et al. Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem Biophys Res Commun. 2007;357:889–895
  9. Leeper NJ, Tedesco MM, Kojima Y, et al. Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. Am J Physiol Heart Circ Physiol. 2009;296:H1329–H1335
  10. Chun HJ, Ali ZA, Kojima Y, et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest. 2008;118:3343–3354
  11. Hashimoto T, Kihara M, Imai N, et al. Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol. 2007;171:1705–1712
  12. Li Z, Bai Y, Hu J. Reduced apelin levels in stable angina. Intern Med. 2008;47:1951–1955
  13. Cordido F, Isidro ML, Nemiña R, Sangiao-Alvarellos S. Ghrelin and growth hormone secretagogues, physiological and pharmacological aspect. Curr Drug Discov Technol. 2009;6:34–42
  14. Kellokoski E, Kunnari A, Jokela M, Mäkelä S, Kesäniemi YA, Hörkkö S. Ghrelin and obestatin modulate early atherogenic processes on cells: enhancement of monocyte adhesion and oxidized low-density lipoprotein binding. Metabolism. 2009;58:1572–1580
  15. Kadoglou NPE, Sailer N, Moumtzouoglou A, et al. Novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrin Diab. 2008;35:661–668
  16. Peters AL, Schriger DL. The new diagnostic criteria for diabetes: the impact on management of diabetes and macrovascular risk factors. Am J Med. 1998;105:15S–19S
  17. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51:606–607
  18. Chandrasekaran B, Dar O, McDonagh T. The role of apelin in cardiovascular function and heart failure. Eur J Heart Fail. 2008;10:725–732
  19. Ronkainen VP, Ronkainen JJ, Hänninen SL, et al. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J. 2007;21:1821–1830
  20. Weir RA, Chong KS, Dalzell JR, et al. Plasma apelin concentration is depressed following acute myocardial infarction in man. Eur J Heart Fail. 2009;11:551–558
  21. Chen MM, Ashley EA, Deng DX, et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation. 2003;108:1432–1439
  22. Halvorsen B, Otterdal K, Dahl TB, et al. Atherosclerotic plaque stability—what determines the fate of a plaque?. Prog Cardiovasc Dis. 2008;51:183–194
  23. Singh V, Deedwania P. Reducing morbidity and mortality in high risk patients with statins. Vasc Health Risk Manag. 2009;5:495–507
  24. Kadoglou NP, Tsanikidis H, Kapelouzou A, et al. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. Metabolism. 2009;E-pub ahead of print
  25. Skilton MR, Celermajer DS. The effects of obesity-related peptides on the vasculature. Curr Vasc Pharmacol. 2006;4:79–85
  26. Caliskan Y, Gorgulu N, Yelken B, et al. Plasma ghrelin levels are associated with coronary microvascular and endothelial dysfunction in peritoneal dialysis patients. Ren Fail. 2009;31:807–813
  27. Yano Y, Toshinai K, Inokuchi T, et al. Plasma des-acyl ghrelin, but not plasma HMW adiponectin, is a useful cardiometabolic marker for predicting atherosclerosis in elderly hypertensive patients. Atherosclerosis. 2009;204:590–594
  28. Genís BB, Granada ML, Alonso N, et al. Ghrelin, glucose homeostasis, and carotid intima media thickness in kidney transplantation. Transplantation. 2007;84:1248–1254
  29. García EA, Korbonits M. Ghrelin and cardiovascular health. Curr Opin Pharmacol. 2006;6:142–147
  30. Kleinz MJ, Maguire JJ, Skepper JN, Davenport AP. Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man. Cardiovasc Res. 2006;69:227–235
  31. Katugampola SD, Pallikaros Z, Davenport AP. [125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with athersclerosis. Br J Pharmacol. 2001;134:143–149
  32. Skilton MR, Nakhla S, Sieveking DP, Caterson ID, Celermajer DS. Pathophysiological levels of the obesity related peptides resistin and ghrelin increase adhesion molecule expression on human vascular endothelial cells. Clin Exp Pharmacol Physiol. 2005;32:839–844
  33. Kellokoski E, Kummu O, Serpi R, et al. Ghrelin vaccination decreases plasma MCP-1 level in LDLR(-/-)-mice. Peptides. 2009;30:2292–2300
  34. Li WG, Gavrila D, Liu X, Wang L, et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation. 2004;109:2221–2226
  35. Avallone R, Demers A, Rodrigue-Way A, et al. A growth hormone-releasing peptide that binds scavenger receptor CD36 and ghrelin receptor up-regulates sterol transporters and cholesterol efflux in macrophages through a peroxisome proliferator-activated receptor gamma-dependent pathway. Mol Endocrinol. 2006;20:3165–3178
  36. Tasci I, Erdem G, Ozgur G, et al. LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Atherosclerosis. 2009;204:222–228
  37. Otto C, Otto B, Frost RJ, et al. Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta Diabetol. 2007;44:65–68
  38. Kadoglou NP, Gerasimidis T, Moumtzouoglou A, et al. Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis. Eur J Vasc Endovasc Surg. 2008;35:661–668

 Supported by the Alexander S. Onassis Public Benefit Foundation.

PII: S1931-5244(10)00029-0

doi: 10.1016/j.trsl.2010.01.004

Translational Research
Volume 155, Issue 5 , Pages 238-246 , May 2010

Article Tools

* Image Usage & Resolution